Astria Therapeutics, Inc. (ATXS)
12.80
-0.11
(-0.85%)
USD |
NASDAQ |
Dec 12, 10:28
Astria Therapeutics Cash from Investing (Quarterly): 52.25M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 13.57M |
| Hologic, Inc. | -132.10M |
| Johnson & Johnson | -542.00M |
| Alnylam Pharmaceuticals, Inc. | 501.11M |
| CorMedix, Inc. | -291.32M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -32.30M |
| Cash from Financing (Quarterly) | 0.003M |
| Free Cash Flow | -120.32M |
| Free Cash Flow Per Share (Quarterly) | -0.5568 |
| Free Cash Flow to Equity (Quarterly) | -31.99M |
| Free Cash Flow to Firm (Quarterly) | -32.30M |
| Free Cash Flow Yield | -16.32% |